Further, a variety of neurological symptoms were clinically diagnosed in hospitalized COVID-19 patients.37,38 Neuropathogenesis could occur due to the neurologic injury resulting from systemic dysfunction,39 dysregulated renin-angiotensin aldosterone system,40 proinflammatory reactions,41,42 para-infectious and post-infectious triggers,43 and direct viral invasion of the nervous system.44–46 As a well characterized neuropsychiatric drug target,47 with the potential to improve lung function, NMDA receptors could be an ideal focal point for future pharmacological interventions of COVID-19. This evidence concerns the gene REN and COVID-19.